Sera Prognostics, Inc. (SERA)
USD 3.29
(5.79%)
USD 3.29
(5.79%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.02 Million USD | 92.66% |
| 2022 | -27.56 Million USD | 53.12% |
| 2021 | -58.8 Million USD | -1109.96% |
| 2020 | -4.86 Million USD | 59.75% |
| 2019 | -12.07 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -2.62 Million USD | -30.02% |
| 2024 Q2 | -3.3 Million USD | -25.79% |
| 2023 Q4 | -2.02 Million USD | 75.09% |
| 2023 Q2 | -29.93 Million USD | -19.01% |
| 2023 FY | -2.02 Million USD | 92.66% |
| 2023 Q1 | -25.15 Million USD | 8.76% |
| 2023 Q3 | -8.11 Million USD | 72.88% |
| 2022 Q2 | -52.28 Million USD | 16.43% |
| 2022 FY | -27.56 Million USD | 53.12% |
| 2022 Q1 | -62.56 Million USD | -6.4% |
| 2022 Q3 | -37.45 Million USD | 28.37% |
| 2022 Q4 | -27.56 Million USD | 26.4% |
| 2021 Q2 | -90.68 Million USD | -54.27% |
| 2021 Q3 | -82.33 Million USD | 9.21% |
| 2021 Q4 | -58.8 Million USD | 28.58% |
| 2021 FY | -58.8 Million USD | -1109.96% |
| 2021 Q1 | -58.78 Million USD | -1109.61% |
| 2020 FY | -4.86 Million USD | 59.75% |
| 2020 Q4 | -4.86 Million USD | 0.0% |
| 2020 Q1 | 21.39 Million USD | 0.0% |
| 2019 FY | -12.07 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 94.875% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 65.81% |
| Aspira Women's Health Inc. | -331 Thousand USD | -510.876% |
| Biodesix, Inc. | 34.3 Million USD | 105.894% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 65.114% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -62.68% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -62.68% |
| Bionano Genomics, Inc. | 34.88 Million USD | 105.797% |
| CareDx, Inc | -47.97 Million USD | 95.785% |
| Check-Cap Ltd. | -24.75 Million USD | 91.832% |
| Castle Biosciences, Inc. | -83.53 Million USD | 97.579% |
| DarioHealth Corp. | -7.54 Million USD | 73.211% |
| Exact Sciences Corporation | 1.94 Billion USD | 100.104% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 97.551% |
| Guardant Health, Inc. | 220.22 Million USD | 100.918% |
| ICON Public Limited Company | 3.56 Billion USD | 100.057% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 100.409% |
| Illumina, Inc. | 1.21 Billion USD | 100.167% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 62.781% |
| iSpecimen Inc. | -2.14 Million USD | 5.841% |
| Standard BioTools Inc. | 46.5 Million USD | 104.348% |
| MDxHealth SA | 18.88 Million USD | 110.707% |
| 23andMe Holding Co. | -141.37 Million USD | 98.57% |
| Medpace Holdings, Inc. | -103.32 Million USD | 98.043% |
| Myriad Genetics, Inc. | 88.1 Million USD | 102.295% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 677.954% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 17.114% |
| NeoGenomics, Inc. | 269.19 Million USD | 100.751% |
| Neogen Corporation | 735.62 Million USD | 100.275% |
| Inotiv, Inc. | 382.14 Million USD | 100.529% |
| Natera, Inc. | -200.1 Million USD | 98.99% |
| OpGen, Inc. | 11.89 Million USD | 117.003% |
| OPKO Health, Inc. | 230.68 Million USD | 100.877% |
| Psychemedics Corporation | 334 Thousand USD | 705.389% |
| Prenetics Global Limited | -43.33 Million USD | 95.334% |
| Prenetics Global Limited | -43.33 Million USD | 95.334% |
| Precipio, Inc. | -386 Thousand USD | -423.834% |
| Personalis, Inc. | -8.02 Million USD | 74.794% |
| RadNet, Inc. | 1.14 Billion USD | 100.176% |
| Sotera Health Company | 2.02 Billion USD | 100.1% |
| Neuronetics, Inc. | 2.79 Million USD | 172.292% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 86.816% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 86.816% |
| Trinity Biotech plc | 63.73 Million USD | 103.172% |
| T2 Biosystems, Inc. | 33.8 Million USD | 105.981% |
| Twist Bioscience Corporation | -192.4 Million USD | 98.949% |
| Exagen Inc. | -12.77 Million USD | 84.168% |